Domperidone, a new dopamine antagonist.
Domperidone is a dopamine antagonist that has recently been released in Canada. Unlike metoclopramide hydrochloride, the other available dopamine antagonist, it does not readily enter the central nervous system. Domperidone acts as both an antiemetic and an upper gastrointestinal tract prokinetic agent. It is rapidly absorbed after oral administration, and few side effects have been reported. Domperidone has been approved for use in Canada for the symptomatic management of upper gastrointestinal tract motility disorders and to prevent gastrointestinal symptoms associated with the use of dopamine agonist agents in Parkinson's disease. The pharmacologic features, indications and side effects of domperidone are reviewed.
D000284:Administration, Oral; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D004294:Domperidone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018492:Dopamine Antagonists; D004415:Dyspepsia / Q000188:drug therapy; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D005769:Gastrointestinal Motility / Q000187:drug effects; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007223:Infant; D008881:Migraine Disorders / Q000188:drug therapy; D009325:Nausea / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy; D013272:Stomach Diseases / Q000188:drug therapy; D013607:Tablets; D014839:Vomiting / Q000517:prevention & control
D018492:Dopamine Antagonists; D013607:Tablets; D004294:Domperidone